Table 1.

Vaccine characteristics for each patient.

Patient No.	Sex	Age, yrs	Vaccine Doses Before Onset of Vasculitis, n	Vaccine	Time Before Symptoms, days	Relapse After New Vaccination
1	Female	82	2	ChAdOx1	5	Missing data
2	Male	20	1	mRNA1273	22	Missing data
3	Male	16	1	BNT162b2	25	Missing data
4	Male	62	2	BNT162b2	14	No new vaccination
5	Male	56	1	ChAdOx1	4	No relapse after 2 other doses of BNT162b2
6	Male	66	1	mRNA1273	17	No relapse after a second dose of mRNA1273
7	Female	52	3	mRNA1273	1	No new vaccination
8	Male	29	2	BNT162b2	4	No new vaccination
9	Female	51	1	BNT162b2	19	No relapse after 2 other doses of BNT162b2
10	Female	36	1	BNT162b2	9	Minimal skin relapse after the second injection (mRNA1273)
11	Female	56	1	BNT162b2	28	No relapse after the third dose of BNT162b2
12	Male	53	1	BNT162b2	8	No new vaccination